Fas-1377A/G and FasL-844 T/C gene polymorphisms and epithelial ovarian cancer


görmüş U., Ergen A., Yilmaz H., DALAN B., Berkman S., Isbir T.

ANTICANCER RESEARCH, cilt.27, sa.2, ss.991-994, 2007 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 27 Sayı: 2
  • Basım Tarihi: 2007
  • Dergi Adı: ANTICANCER RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.991-994
  • Anahtar Kelimeler: Fas/FasL pathway, immune privilege, polymorphism, ovarian cancer, ANTIGEN-MEDIATED APOPTOSIS, CELL-DEATH, FAS LIGAND, PATHWAY, ACTIVATION, EXPRESSION, RISK
  • İstanbul Üniversitesi Adresli: Evet

Özet

Background: The Fas receptor is known to be widely expressed in various tissues and FasL is highly expressed on cells of the immune system and also on cells of immune-privileged areas such as the eyes and brain. Ovarian cells are known to exhibit marked FasL immunoreactivity throughout follicular development; there may also be a relationship between Fas and FasL polymorphisms and the immune privileges of the epithelial ovarian cells. Patients and Methods: The study included 47 epithelial ovarian carcinoma patients and 41 healthy subjects. Polymerase chain reaction (PCR) and restriction endonucleases were used to determine the polymorphic Fas and FasL genes. Results: The FasL CC genotype was found to increase the risk of ovarian carcinoma and a protective effect of the GGCT genotype was observed. Conclusion: Because of the expressional aspects of the FasL -844T -> C polymorphism, individuals carrying the FasL-844C allele would be expected to have higher FasL expression on tumour cells compared with those carrying the FasL-844T allele. People with such a genotype show a tendency to develop various tumours.